<DOC>
	<DOCNO>NCT01717807</DOCNO>
	<brief_summary>The EGFR one frequently overexpressed proteins various cancer include lung cancer , related tumor progression resistance treatment . New treatment strategy target EGFR develop : `` although much work remain do , erlotinib already establish part therapeutic armamentarium cancer '' ( A review erlotinib clinical use . Tang PA , Tsao MS , Moore MJ . Expert Opin Pharmacotherapy . 2006 Feb ; 7 ( 2 ) :177-93 . ) Noninvasive PET/CT image EGFR expression activity mutation status NSCLC could aid selection patient individualized therapy EGFR kinase inhibitor . Whole-body noninvasive PET/CT imaging could estimate treatment-responsive vs. -resistant tumor burden initiation therapy EGFR inhibitor . The purpose study : 1 . To adjust optimal treatment patient tumor high expression EGFR identification type cancer use C11-Erlotinib PET/CT pretreatment work-up ; well follow treatment response . 2 . To recognize patient advanced pancreatic cancer respond treatment erlotinib distinguish non-responders .</brief_summary>
	<brief_title>C11-Erlotinib PET/CT Tool Identification Characterization Tumor With High Expression Epidermal Growth Factor Receptor ( EGFR ) .</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>patient NSC type lung cancer high expression EGFR candidate erlotinib second / third line treatment ; patient advance pancreatic tumor candidate complex gemcitabine erlotinib treatment . lack histological diagnosis ; candidate erlotinib ; pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>epithelial growth factor receptor</keyword>
	<keyword>lung cancer</keyword>
	<keyword>advanced tumor pancrease</keyword>
	<keyword>erlotinib</keyword>
	<keyword>C11-Erlotinib PET/CT</keyword>
</DOC>